Background: Permanent arteriovenous (AV) access is the preferred access for dialysis delivery in children and adolescents requiring chronic hemodialysis (HD). Ultrasound dilution (UD) monitoring of AV access flow is widely used in adult HD units for the early detection of stenosis but experience in pediatrics is limited. Methods: We monitored all maintenance HD patients with AV access using a noninvasive screening algorithm based on UD access flow. We assessed the effectiveness of this algorithm by comparing it to fistulagrams and its impact on AV access-related morbidity. Results: AV access thrombosis rates fell from 13.5 per 100 patient-months on HD during the baseline period to 3.5 per 100 patient-months on HD during the screening period (p < 0.04). The mean blood flow rate by UD measurement was lower in AV accesses that went on to thrombose compared to those without thrombosis (1,203 ml/min/1.73 m2 vs. 1,683 ml/min/1.73 m2, p < 0.001). When compared to fistulagrams, the screening algorithm was 94% sensitive and 77% specific in detecting hemodynamically significant stenosis, with positive and negative predictive values of 83 and 91% respectively. Conclusions: A noninvasive UD screening algorithm of AV access flow is very sensitive in detecting hemodynamically significant stenosis and can decrease AV access thrombosis rates.

Keywords:
Ultrasound dilution, Vascular access, Hemodialysis, Quality improvement
1.
National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: hemodialysis adequacy, peritoneal dialysis adequacy and vascular access. Am J Kidney Dis 2006;48(suppl 1):S1-S322.
2.
Fadrowski JJ, Hwang W, Neu AM, Fivush BA, Furth SL: Patterns of use of vascular catheters for hemodialysis in children in the United States. Am J Kidney Dis 2009;53:91-98.
3.
Sheth RD, Brandt ML, Brewer ED, Nuchtern JG, Kale AS, Goldstein SL: Permanent hemodialysis vascular access survival in children and adolescents with end-stage renal disease. Kidney Int 2002;62:1864-1869.
4.
Kumbar L, Karim J, Besarab A: Surveillance and monitoring of dialysis access. Int J Nephrol 2012;2012:649735.
5.
Goldstein SL, Allsteadt A: Ultrasound dilution evaluation of pediatric hemodialysis vascular access. Kidney Int 2001;59:2357-2360.
6.
Goldstein SL, Allsteadt A, Smith CM, Currier H: Proactive monitoring of pediatric hemodialysis vascular access: effects of ultrasound dilution on thrombosis rates. Kidney Int 2002;62:272-275.
7.
Goldstein SL, Smith CM, Currier H: Noninvasive interventions to decrease hospitalization and associated costs for pediatric patients receiving hemodialysis. J Am Soc Nephrol 2003;14:2127-2131.
8.
Chand DH, Valentini RP: International pediatric fistula first initiative: a call to action. Am J Kidney Dis 2008;51:1016-1024.
9.
Chand DH, Bednarz D, Eagleton M, Krajewski L: A vascular access team can increase AV fistula creation in pediatric ESRD patients: a single center experience. Semin Dial 2009;22:679-683.
10.
May RE, Himmelfarb J, Yenicesu M, et al: Predictive measures of vascular access thrombosis: a prospective study. Kidney Int 1997;52:1656-1662.
11.
Neyra NR, Ikizler TA, May RE, et al: Change in access blood flow over time predicts vascular access thrombosis. Kidney Int 1998;54:1714-1719.
12.
Tonelli M, James M, Wiebe N, Jindal K, Hemmelgarn B: Ultrasound monitoring to detect access stenosis in hemodialysis patients: a systematic review. Am J Kidney Dis 2008;51:630-640.
13.
Casey ET, Murad MH, Rizvi AZ, et al: Surveillance of arteriovenous hemodialysis access: a systematic review and meta-analysis. J Vasc Surg 2008;48(5 suppl):48S-54S.
14.
Schwab SJ, Oliver MJ, Suhocki P, McCann R: Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 2001;59:358-362.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.